Legend Biotech, widely recognized for its collaboration with Johnson & Johnson (J&J) on the BCMA CAR-T therapy Carvykti, has found itself at the center of buyout speculation, which has reverberated across biotech markets. Reports of an acquisition bid prompted the company to engage Centerview
The biopharmaceutical industry is witnessing major advancements in cell therapy, with CAR-T therapies surfacing as a pioneering avenue for treating complex diseases. The latest development in this field is the expanded strategic collaboration between IASO Biotechnology (IASO Bio) and Innovent
The landscape of Chimeric Antigen Receptor T-cell (CAR-T) therapies is witnessing rapid evolution as emerging companies introduce innovative solutions to overcome existing challenges. These therapies, which involve genetically engineering a patient’s T cells to target cancer cells, have shown
Natural Killer (NK) cell therapy, once a promising beacon for cancer treatment, is now being repositioned as a potential game-changer in the management of autoimmune diseases. Biotech companies, like Artiva Biotherapeutics, are shifting their focus to explore the untapped potential of NK cell
The recent breakthrough in CAR T-cell manufacturing is nothing short of revolutionary. Researchers from the Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at the Singapore-MIT Alliance for Research and Technology (SMART), in collaboration
Recent clinical advancements by PolTREG, a pioneering Polish biotechnology company, have cast a hopeful light on the treatment of type-1 diabetes (T1D). The company's breakthrough Treg therapy, PTG-007, has shown great promise in fundamentally altering the management of this autoimmune disease. T1D
